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Abstract: Meta-analyses suggest normalizing effects of methylphenidate on structural fronto-striatal 
abnormalities in patients with attention-deficit/hyperactivity disorder (ADHD). A subgroup of 
patients receives atypical antipsychotics concurrent with methylphenidate. Long-term safety and 
efficacy of combined treatment are unknown. The current study provides an initial investigation of 
structural brain correlates of combined methylphenidate and antipsychotic treatment in patients 
with ADHD. Structural magnetic resonance imaging was obtained in 31 patients who had received 
combined methylphenidate and antipsychotic treatment, 31 matched patients who had received 
methylphenidate but not antipsychotics, and 31 healthy controls (M age 16.7 years). We analyzed 




eight subcortical-limbic volumes of interest, each involved in dopaminergic neurotransmission. 
Patients in the combined treatment group, but not those in the methylphenidate only group, 
showed a reduction in total cortical volume compared to healthy controls (Cohen’s d=0.69, 
p<0.004), which was apparent in most frontal volumes of interest. Further, the combined treatment 
group, but not the methylphenidate group, showed volume reduction in bilateral ventral 
diencephalon (Left: Cohen’s d=0.48, p<0.04; Right: Cohen’s d=0.46, p<0.05) and the left 
thalamus (Cohen’s d=0.47, p <0.04). These findings may indicate antipsychotic treatment 
counteracting the normalizing effects of methylphenidate on brain structure. However, it cannot be 
ruled out that pre-existing clinical differences between both patient groups may have resulted in 
anatomical differences at the time of scanning. The absence of an untreated ADHD group hinder 
unequivocal interpretation and implications of our findings.  
 








Attention-deficit/hyperactivity disorder (ADHD) is characterized by age-inappropriate hyperactivity, 
impulsivity, and/or inattention. Subtle though widespread differences in brain morphology have been found in 
patients with ADHD, the most replicated being reduced volumes of the basal ganglia including the caudate, 
putamen, and globus pallidus, and of frontal regions [1]–[3]. Treatment with methylphenidate is the medical 
intervention of first choice [4]. Neuroimaging studies investigating the effect of methylphenidate on brain structure 
and function in children with ADHD consistently suggest normalizing effect. At least partial normalization has been 
reported for volumes of the anterior cingulate cortex, thalamus, inferior frontal gyrus, right precentral gyrus, right 
parieto-occipital gyrus, and the cerebellar vermis [5].  
In a subgroup of patients with ADHD, stimulant treatment is combined with atypical antipsychotics such as 
risperidone or pipamperone. Antipsychotics have been recommended by an expert group for the treatment of 
comorbid disruptive behavior and severe aggression in ADHD [6]. Besides disruptive behavior, co-morbid pervasive 
developmental disorder (PDD) has been found to be predictive of the prescription of antipsychotics [7]. In the 
Netherlands, atypical antipsychotics are prescribed to 8% of stimulant-treated children with ADHD [7]. Increasing 
prescription rates of atypical antipsychotics to children and adolescents [8] have raised concerns [9].  
Abnormalities in dopaminergic neurotransmission have been reported in patients with ADHD, and include 
increased levels of striatal dopamine auto-receptors and reduced dopamine metabolism in the frontal cortex [10]. 
Both methylphenidate and atypical antipsychotics exert their effects by interacting with dopaminergic 
neurotransmission, albeit with opposite modes of action. Methylphenidate blocks dopamine reuptake and stimulates 
dopamine release from the presynaptic cell, resulting in increased synaptic levels of dopamine [11]. Most atypical 
antipsychotics, by contrast, are dopamine antagonists blocking the effects of dopamine in the synapse by occupying 
the postsynaptic dopamine D2 receptors. It has been suggested that combined treatment with methylphenidate and 
antipsychotics may compromise the effects of each of the individual agents [12]. Large-scale studies on long-term 
safety and efficacy of combined treatment have not yet been performed [13].  
Little is known about the possible effects of atypical antipsychotic treatment on structural brain 
development in children. The few studies investigating the neural effects of antipsychotics in pediatric populations 
have been limited to childhood-onset schizophrenia and pediatric bipolar disorder. Frazier et al. [14] reported a trend 




others found no such effect [15]. Despite increasing prescription rates, no studies have yet investigated the effects of 
atypical antipsychotic treatment on brain development in children with ADHD.  
The current cross-sectional, observational MRI study investigated brain correlates of combined 
methylphenidate and atypical antipsychotics treatment in patients with ADHD, in comparison to patients who had 
received methylphenidate only, and to healthy control subjects. In the absence of a medication-naïve ADHD group 
and of pretreatment measurements, we were unable to directly investigate whether concurrent antipsychotic 
treatment would counteract any normalizing effects of methylphenidate treatment on brain structure. However, 
based on the opposing synaptic effects of the two substances, we expected to find volume reductions in frontal-
striatal regions in patients who had received combined treatment compared to healthy control participants, and that 






This study was part of NeuroIMAGE [16], the follow-up of the Dutch part of the International Multicenter 
ADHD Genetics (IMAGE) study [17]. The NeuroIMAGE sample consists of 1045 children from 330 ADHD and 
154 control families, who met the following inclusion criteria: age between 5-30 years, of European Caucasian 
descent, an IQ ≥ 70, and no diagnosis of autistic disorder, general learning difficulties, brain disorders, or known 
genetic disorders. All subjects who successfully underwent diagnostic assessment and structural MRI scanning were 
considered for inclusion in the current study. First, all participants with ADHD who received combined treatment 
with (1) any methylphenidate preparation and (2) atypical antipsychotics, either in the past or currently and for a 
minimum duration of thirty days, were included in the study sample (MPH+AAP group). Next, two one-to-one age- 
and gender-matched control samples were drawn: a methylphenidate group (MPH group) consisting of participants 
with ADHD with current or past methylphenidate treatment with a minimum duration of 30 days and no treatment 
with antipsychotics and a healthy control group (HC group) consisting of participants with no psychiatric diagnosis 
and no current or past treatment with psychoactive medication of any type. Informed consent was signed by all 









The Dutch translation of the Schedule for Affective Disorders and Schizophrenia for School-Age Children 
- Present and Lifetime Version (K-SADS [18]) was administered. In addition, all participants were administered the 
Conners Parent Rating Scale - Revised (Long version, CPRS-R:L [19]) combined with either the Conners Teacher 
Rating Scale - Revised (Long version, CTRS-R:L [20]) for participants < 18 years old, or the Conners Adult ADHD 
Rating Scales - Self-Report (Long Version, CAARS-S:L [21]) for participants ≥ 18 years old. For participants using 
medication, ratings reflected their functioning while they were off medication. 
Scores on the K-SADS interview and Conners questionnaires were restructured to match the DSM 5 
criteria for ADHD. Participants with ADHD had to fulfill the following criteria: (1) six or more symptoms of 
hyperactivity/impulsivity and/or inattentiveness (five for participants ≥ 18 old), (2) meet DSM 5 criteria for 
pervasiveness of symptoms and impact on daily functioning, (3) symptom onset before the age of 12 years, and (4) 
T ≥ 63 on at least one of the ADHD scales on either one of the Conners questionnaires. Two participants who 
fulfilled all criteria but one for a full ADHD diagnosis were classified as mild ADHD cases. ADHD type 
(predominantly hyperactive/impulsive, predominantly inattentive, or combined type), impairment in daily 
functioning (Children’s Global Assessment Scale, CGAS [22]) and co-morbidity were assessed using the K-SADS 
interview. Mild PDD symptoms were assessed with the Children’s Social Behavior Questionnaire (CSBQ [23]). 
Healthy control participants were required to have less than three ADHD symptoms (two for participants ≥ 18 years 
old) and T < 63 on each of the scales of all Conners’ questionnaires.  
From pharmacy transcripts, the following parameters were obtained for each type of psychoactive 
medication used: treatment duration, age of treatment initiation and cessation,  mean daily dose, and current vs. past 
user. If pharmacy transcripts were incomplete (n=19, 31%), information from parent-report questionnaires was used.  
  





MRI data was acquired at 1.5 Tesla on a Siemens Sonata scanner at the VU Medical Centre in Amsterdam 
and on a Siemens Avanto scanner at the Donders Centre for Cognitive Neuroimaging in Nijmegen (Siemens, 
Germany). A standard identical 8-channel phased array coil model was used at both sites and all scan parameters 
were matched as closely as possible. A T1-weighted 3D MP-RAGE scan was acquired with parallel imaging by 
generalized auto-calibrating partially parallel acquisition (GRAPPA; 176 sagittal slices, voxel size 1 x 1 x 1 mm, 
FOV = 256 x 256 x 176 mm).  
Cortical reconstruction and volumetric segmentation was performed with FreeSurfer software version 5.3 
with default settings (http://surfer.nmr.mgh.harvard.edu/). FreeSurfer is an image processing pipeline including a 
volume-based route to subcortical segmentation [24] and a surface-based route to create a 3D reconstruction and 
parcellation of the cortical sheet [25]. From FreeSurfer parcellations [26] and segmentations, we calculated total 
cortical and subcortical volume, and selected eight bilateral subcortical and limbic volumes of interest (VOIs; 
bilateral ventral diencephalon, putamen, caudate nucleus, globus pallidus, nucleus accumbens area, hippocampus, 
amygdala, and thalamus) and seven bilateral frontal cortical VOIs (inferior frontal gyrus [IFG; sum of pars orbitalis, 
pars triangularis, and pars opercularis], orbitofrontal gyrus [OFG; sum of medial orbitofrontal gyrus and lateral 
orbitofrontal gyrus], middle frontal gyrus [MFG; sum of caudal middle frontal gyrus and rostral middle frontal 
gyrus], superior frontal gyrus [SFG], anterior cingulate gyrus [ACC; sum of caudal anterior cingulate cortex and 




 Treatment group (HC, MPH, or MPH+AAP) was entered in two univariate linear mixed regression models 
predicting standardized total cortical and subcortical volume. Dummy variables modeled between-group contrasts 
(MPH+AAP vs. HC, MPH vs. HC, and MPH+AAP vs. MPH; the third contrast was tested in a second run of the 
model). Age, gender, and scanner location were entered as fixed covariates. To correct for family relatedness within 
the sample, a random family intercept was modeled. Restricted Maximum Likelihood (REML) was applied for 
model estimation.  
We analyzed between-group effects in (1) the subcortical-limbic VOIs, (2) the right, and (3) left frontal 




variables for between-group contrasts. The VOI analyses were initially ran without total cortical or subcortical 
volume as a covariate. If there was a significant (α<0.05) effect of treatment group on total cortical or subcortical 
volume, totals were added to the model to investigate the local effects that could not be accounted for by global 
effects. For each significant between-group effect, effect size (Cohen’s d [27]) was calculated as the difference 
between the estimated marginal means divided by their pooled standard deviations. False discovery rate (FDR) 
procedures (maximum acceptable FDR of 5%) accounted for multiple hypothesis testing [28].  
Structural brain differences between groups may be mediated by pre-existing clinical differences between 
groups (e.g. in symptom severity), but adding such measures to the model as covariates eliminates variance of 
interest [29]. Continuous variables of significant difference between both treatment groups were thus entered as 
covariates only in a secondary step to provide an exploratory analysis of possible confounders. The contribution of 
the covariates to between-group differences was assessed for each contrast by calculating the range of changes in 
effect size (Cohen’s dmodel with covariate–Cohen’s dinitial model) and p-values, and the average of absolute changes in effect 
size and p-value, within brain volumes affected by treatment group. For categorical factors that may have 
confounded the results, sensitivity analyses were performed by repeating the analyses in each subgroup (e.g. patients 




Clinical sample characteristics  
 
The sample consisted of 93 participants from 87 families, between the ages of 10 and 24 years with no age 
differences between the three participant groups (HC: M=16.7, SD=3.3, range=10.6-24.8; ADHDMPH: M=16.6, 
SD=3.0, range=10.6-22.3; ADHDMPH+AAP: M=16.7, SD=3.3, range=10.2-24.2). Eighty-four percent of participants 
were male and 50% participated in Amsterdam, both variables being equally distributed over the three groups 
(Chi2gender=0.000, p=1.00; Chi2location=2.409, p<.300). IQ in the ADHD sample was lower than in the healthy control 
sample (MHC=103.26, MADHD=96.11, t=2.235, p=0.028), as was CGAS-score of daily functioning (MHC=89.67, 
MADHD=61.45, t=17.254 p=0.001). Patients in the MPH+AAP group had more ADHD symptoms than the MPH 




autism spectrum questionnaire) between both ADHD groups (Table 1). Comorbid diagnoses included ODD/CD 
(nMPH=10; nMPH+AAP=14; Chi2=1.088, p=0.297), anxiety disorders (nMPH=2; nMPH+AAP=0; Chi2=2.067, p=0.151), and 
tic disorders (nMPH=1; nMPH+AAP=1; Chi2=0.000, p=1.000), which were equally distributed across the two groups.  
Within all patients who had been medicated, 81% had been prescribed immediate-release methylphenidate 
preparations (n=50), 90% extended-release methylphenidate preparations (n=56), and 15% dexamphetamine 
preparations (n=9). The majority of patients had a treatment history of more than one stimulant type (n=46, 74%). 
Sixty-one percent (n=38) of patients received stimulant treatment within three months prior to scan (current users). 
Stimulant treatment duration ranged from 0.1 to 12.1 years with a mean(SD) of 5.4(3.3) years. We found no 
between-group differences regarding stimulant treatment duration, age of stimulant treatment onset, age of treatment 
cessation, mean daily dose, and the proportion of current users (Table 1). Although not significant, more patients in 
the MPH+AAP group had a history of psychotropic medication treatment other than MPH+AAP. Medication other 
than MPH or AAP included clonidine (nMPH=1; nMPH+AAP=5), atomoxetine (nMPH=3; nMPH+AAP=15), melatonin 
(nMPH=13; nMPH+AAP=19), antidepressants (nMPH=1; nMPH+AAP=5), and anxiolytics (nMPH=1; nMPH+AAP=1). A history of 
atomoxetine use was significantly more prevalent in the combined treatment group compared to in the MPH only 
group (Chi2=11.3, p=0.001). 
In the MPH+AAP group, most patients had been prescribed risperidone (n=24), with a mean daily dose of 
1.2 mg; other antipsychotics were pipamperone (n=8), quetiapine (n=1), olanzapine (n=1), and aripiprazole (n=1). 
Four participants had a history of two antipsychotic agents. Antipsychotic treatment duration ranged from 0.2 to 
10.9 years (mean=3.7, SD=2.9), and age of antipsychotic treatment initiation ranged from 2.6 to 17.2 years 
(mean=10.7, SD=3.7). Fifty-eight percent of patients (n=18) had ceased AAP treatment at least three months, and on 
average 3.8 years (SD=2.7), prior to scan.  
 
Subcortical-limbic volumes  
 
There were no differences in total subcortical volume between the three groups. Local volume reductions 
approaching moderate effect sizes were found in the MPH+AAP group compared to the HC group (Figure 1), in the 
left (β=-0.5204, puncorrected<0.04, Cohen’s d=0.48) and right (β=-0.4919, puncorrected=0.05, Cohen’s d=0.46) ventral 




the right thalamus, but this effect only approached significance (β=-0.471, puncorrected=0.058, Cohen’s d=0.44). No 
between-group effects survived FDR-correction for multiple testing. There were no local volume differences 
between the MPH and HC group, or between the MPH and MPH+AAP group. 
 




Total cortical volume was reduced in the MPH+AAP group compared to the HC group with moderate 
effect size (puncorrected=0.004; Cohen’s d=0.69; pFDR-corrected<0.075), but not between the MPH and HC group or 
between the MPH and MPH+AAP group. Results from the cortical VOI analyses are summarized in Table 2 and 
Figure 2A. The MPH+AAP group showed significant volume reductions compared to the HC group in bilateral 
precentral gyrus, IFG, OFG, SFG, MFG, and left ACC, with effect sizes ranging from small (Cohen’s d=0.47 in left 
MFG) to large (Cohen’s d=0.80 in left ACC and right precentral gyrus). Effects in the right precentral gyrus (pFDR-
corrected=0.028) and left ACC (pFDR-corrected=0.028) survived correction for multiple testing. The MPH group showed 
volume reductions compared to HC in the right SFG, the right OFG, and the left ACC, with moderate effect sizes 
ranging from 0.47 to 0.77, of which left ACC volume reduction survived correction for multiple comparisons (pFDR-
corrected=0.028). Comparing MPH to MPH+AAP yielded a significant difference of moderate effect size in the right 
precentral gyrus (Cohen’s d=0.58), which did not survive FDR-correction. Total cortical volume was added to the 
model to assess local rather than global effects. After adding total cortical volume, left ACC volume was reduced in 
both the MPH+AAP group (p=0.001; Cohen’s d=0.72) and the MPH group (p=0.03; Cohen’s d=0.49) compared to 
the HC group. Volume reduction in the MPH+AAP group survived FDR-correction (pFDR-corrected=0.042).  
 
{figure 2 here} 
 





Since the MPH+AAP group displayed more ADHD symptoms, greater functional impairment, and more 
patients with a history of atomoxetine treatment than the MPH group, we explored the contribution of these factors 
to structural brain differences. Adding total symptom count to the model affected the effect sizes and p-values in 
each contrast and in each brain region (Figure 2B, Table 3). Average absolute change in effect sizes (Cohen’s d(model 
with symptom count)–Cohen’s d(initial model)) across brain regions affected by treatment group was 0.23 for the MPH+AAP vs. 
HC contrast (range: -0.66 to 0.21), 0.18 for the MPH vs. HC contrast (range: -0.61 to 0.29) and 0.05 (range: -0.02 to 
0.10) for the MPH vs. MPH+AAP contrast. The absolute average change in p-values was 0.25 and 0.30 for MPH vs. 
MPH+AAP and MPH vs. HC, respectively, and 0.06 for the MPH vs. MPH+AAP contrast. Adding CGAS scores for 
daily functioning to the model had a very similar effect: average absolute change in effect size was 0.20 for 
MPH+AAP vs HC, 0.14 for MPH vs HC and 0.05 for MPH vs. MPH+AAP. Average absolute change in p-values 
was 0.21 for MPH+AAP vs HC, 0.24 for MPH vs HC and 0.03 for MPH vs. MPH+AAP. Thus, adding symptom 
count or functional impairment scores to the model influenced effect sizes and p-values in contrasts involving HC 
subjects, but had a minimal impact on the contrast between the two treatment groups (Table 3).  
Last, the combined treatment group contained more patients with a history of atomoxetine treatment. To 
evaluate the possible confounding effect of atomoxetine treatment history, all tests with significant results were 
repeated in atomoxetine-naïve patients only. Our findings remained unchanged: excluding atomoxetine users did not 
change the direction of effect in any VOI, and all but three (left thalamus in the MPH+AAP vs HC contrast, right 
superior frontal gyrus in the MPH vs HC contrast, and right precentral gyrus in the MPH vs MPH+AAP contrast) p-




This study intended to provide an initial investigation of long-term structural brain correlates of combined 
methylphenidate and atypical antipsychotics treatment in adolescent patients with ADHD. Compared to unaffected 
peers, patients who had received combined treatment showed reduced total cortical volume, which was reflected in 
volume reductions across the frontal cortex. In addition, these patients showed reduced local volumes of the bilateral 
ventral diencephalon and the left thalamus. Patients treated with methylphenidate solely, by contrast, showed no 




volumes of interest. Patients in the MPH+AAP group displayed more ADHD symptoms, functional impairment, and 
comprised a higher incidence of atomoxetine users compared to patients in the MPH only group. Adding these 
covariates to the model had minimal impact on differences in brain structure between the two ADHD groups.  
Reduced total cortical volume and frontal cortical volumes are among the most replicated findings in 
ADHD and have repeatedly been shown to be normalized in patients using psycho-stimulants [3], [30], [31]. Within 
the frontal cortex, we found little evidence of spatial specificity. The reduction of total cortical volume in the 
MPH+AAP group is reflected in all frontal regions of interest except the frontal poles. All frontal volume reductions 
in the MPH+AAP group were driven by total cortical volume reduction, with the exception of left ACC volume 
reduction. However, left ACC volume reduction was also found in the MPH group. Cortical volume reduction 
associated with combined methylphenidate and antipsychotic treatment thus appears to be global rather than local. 
This is in line with previous studies suggesting that ADHD itself may be associated with global rather than local 
cortical changes [2]. It is less clear whether stimulants have local or global effects on brain structure, since the 
majority of previous studies adopted a regions of interest approach. Future investigations of the effects of stimulants, 
antipsychotics, and combined treatment may benefit from a whole-brain approach. 
In the subcortical-limbic regions, we found volume reduction in the bilateral ventral diencephalon and left 
thalamus in the combined treatment group, but not in the methylphenidate only group. The ventral diencephalon 
includes the subthalamic nuclei and substantia nigra. The subthalamic nuclei are strongly connected within the basal 
ganglia, and have been attributed an important role in response inhibition [32]. The substantia nigra is the largest 
dopaminergic nucleus in the human brain, strongly connected to the striatum, and is thought to play an important 
role in reward [33] and movement [34]. The ventrolateral portion of the thalamus relays and modulates 
neurotransmission in the frontostriatal circuits, connecting the cerebellum and basal ganglia to the cortical motor 
areas. Although these thalamic and subthalamic functions are highly relevant to the clinical presentation of ADHD, 
the role of thalamic and subthalamic nuclei in ADHD pathophysiology remains poorly understood. Thalamic 
volume reduction [35], altered left thalamic morphology and structural connectivity [37], and normalized thalamic 
morphology with methylphenidate treatment [35] have previously been reported in ADHD. We found no previous 
reports of thalamic or subthalamic changes with childhood antipsychotic treatment. Further investigation of thalamic 
and subthalamic structures in ADHD and their susceptibility to treatment, is needed to interpret the thalamic and 




The current study was explorative and we warrant cautious interpretation of our findings. Participants in the 
MPH+AAP group showed more pronounced structural brain changes relative to healthy controls than stimulant-
treated patients with ADHD, thereby resembling the non-medicated patient groups in previous studies [38]. Volume 
reductions in the combined treatment group but not in the methylphenidate only group could be indicative of 
counteractive effects of methylphenidate and atypical antipsychotics. That is, the opposing mechanism of action 
may compromise the synaptic effects of both individual agents, resulting in attenuation of structural normalization 
typically occurring with methylphenidate treatment. However, the current study did not allow direct investigation of 
this hypothesis and multiple interpretations are possible. Two shortcomings in study design prevent us from 
rejecting two plausible alternative interpretations.  
First, our study was observational and cross-sectional. Our study is in many ways different from 
randomized controlled trials (RCTs), which are considered the gold standard when investigating treatment effects. 
First, in the current study no pre-treatment measurement was performed. The structural changes in the combined 
treatment group may be the cause rather than the result of medication intake (i.e. antipsychotic treatment may be 
assigned to patients at higher risk for cortical volume reduction). Pre-treatment measurements are needed to exclude 
this possibility. As a substitute to pre-treatment assessment, we explored the contribution of several clinical 
measures at time of scan. Our findings suggested that adding such variables to the model only minimally affected 
differences between the combined treatment group and the methylphenidate only group. However, the possibility of 
pre-treatment differences confounding treatment effects cannot be excluded, and the exploratory analyses we 
applied are not conclusive in this respect. Second, due to the absence of a matched stimulant-naïve patient sample, 
we were unable replicate previous findings of structural normalization with methylphenidate treatment in the current 
sample. Future studies would benefit from the  inclusion of a stimulant naïve patient group, to enable the 
interpretation of the individual contributions of both stimulant and antipsychotic treatment on brain structure. 
Besides these two essential caveats for correct interpretation of our findings, several other limitations 
should be kept in mind. The naturalistic study design resulted in a heterogeneous patient sample, and the age-range 
of participants was very wide. The combined treatment group included patients who were receiving treatment within 
a week prior to scanning as well as patients who had ceased treatment years before study participation, and patients 
who initiated treatment before the age of four as well as patients who initiated treatment after the age of sixteen. Due 




medication and daily dose within the combined treatment group. Increased variance within our sample may have 
limited our ability to detect clinically meaningful effects. Apart from being heterogeneous, our sample was also 
relatively small, and subtle brain changes of small effect size may therefore have gone undetected. In line with this, 
most of our findings did not survive FDR correction for multiple testing. Last, as we were unable to obtain complete 
medication transcripts from all pharmacies, our data may have been subject to recall bias. Although a recent report 
suggested that recall bias may be limited in ADHD [39], it cannot be fully excluded, given our long-term 
retrospective study design. 
At the same time, there are several advantages to our study design. Large-scale observational cohort 
studies, such as the current study, investigate patients that are representative of the heterogeneous clinical 
population, which enhances generalizability. Moreover, observational studies allow the investigation of complex 
treatment patterns in vulnerable patient groups, such as children with ADHD [40]. Results from observational 
studies are generally more consistent than results of RCTs and susceptibility bias does not typically result in an 
overestimation of treatment effects [41], [42]. Moreover, neuroimaging is a valid tool to investigate treatment safety 
and efficacy in observational study designs [43]. Therefore, while awaiting replication, the current study may have 
implications. Our findings, although preliminary, raise concern and stress the need for clinical guidelines for the 
prescription of these agents [44]. Furthermore, they emphasize that future studies investigating the effects of 
methylphenidate on the developing brain should carefully document co-medication with dopaminergic agents, 
including atypical antipsychotics.  
In conclusion, we found reduced total cortical volume, that was reflected in local frontal volume 
reductions, as well as volume reductions in the bilateral ventral diencephalon and left thalamus, in patients with 
ADHD who had received combined methylphenidate and atypical antipsychotic treatment. These structural 
anomalies were smaller or absent in patients who were treated with methylphenidate solely. Longitudinal studies, 
including pre-treatment measurements and a stimulant-naïve patient group, are needed to allow more conclusive 
interpretation of potential mechanisms leading to these volume reductions.   
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